Inhibition of TWEAK activity as a new treatment for inflammatory and degenerative diseases

Drug News and Perspectives

Volumn 19, Issue 10, 2006, Pages 589-595

  Yepes, Manuel ^a,c   Winkles, Jeffrey A ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Center for Neurodegenerative Disease   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; NEUROPROTECTIVE AGENT; TNFSF12 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ANGIOGENESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BLOOD BRAIN BARRIER; BRAIN EDEMA; CANCER; CARCINOMA CELL; CEREBROVASCULAR ACCIDENT; COLON CARCINOMA; DEGENERATIVE DISEASE; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; CAROTID ARTERY DISEASE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BRAIN EDEMA; CAROTID ARTERY DISEASES; CEREBROVASCULAR ACCIDENT; HUMANS; MULTIPLE SCLEROSIS; NEOPLASMS; NEUROPROTECTIVE AGENTS; OBESITY; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 34247630755     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2006.19.10.1068005     Document Type: Review

References (65)

1. Chicheportiche, Y., Bourdon, P.R., Xu, H. et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997, 272: 32401-10.
2. Wiley, S.R. and Winkles, J.A. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003, 14: 241-9.
3. Kawakita, T., Shiraki, K., Yamanaka, Y. et al. Functional expression of TWEAK in human hepatocellular carcinoma: Possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun 2004, 318: 726-33.
4. Kawakita, T., Shiraki, K., Yamanaka, Y. et al. Functional expression of TWEAK in human colonic adenocarcinoma cells. Int J Oncol 2005, 26: 87-93.
5. Maecker, H., Varfolomeev, E., Kischkel, F. et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005, 123: 931-44.
6. Felli, N., Pedini, F., Zeuner, A. et al. Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J Immunol 2005, 175: 1464-72.
7. Chacon, M.R., Richart, C., Gomez, J.M. et al. Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine 2006, 33: 129-37.
8. Meighan-Mantha, R.L., Hsu, D.K., Guo, Y. et al. The mitogen-inducible Fn14 gene encodes a type 1 transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999, 274: 33166-76.
9. Wiley, S.R., Cassiano, L., Lofton, T. et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001, 15: 837-46.
10. Brown, S.A.N., Hanscom, H.N., Vu, H., Brew, S.A. and Winkles, J.A. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J 2006, 397: 297-304.
11. Brown, S.A.N., Richards, C.M., Hanscom, H.N., Feng, S.L. and Winkles, J.A. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor- associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J 2003, 371: 395-403.
12. Tran, N.L., McDonough, W.S., Savitch, B.A. et al. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005, 280: 3483-92.
13. Winkles, J.A., Tran, N.L. and Berens, M.E. TWEAK and Fn14: New molecular targets for cancer therapy? Cancer Lett 2006, 235: 11-7.
14. Saitoh, T., Nakayama, M., Nakano, H. et al. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003, 278: 36005-12.
15. Bossen, C., Ingold, K., Tardivel, A. et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 2006, 281: 13964-71.
16. Feng, S.L., Guo, Y., Factor, V.M. et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000, 156: 1253-61.
17. Tanabe, K., Bonilla, I., Winkles, J.A. and Strittmatter, S.M. Fibroblast growth factor-inducible-14 is induced in axotomized neurons and promotes neurite outgrowth. J Neurosci 2003, 23: 9675-86.
18. Potrovita, I., Zhang, W., Burkly, L. et al. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 2004, 24: 8237-44.
19. Yepes, M., Brown, S.A., Moore, E.G. et al. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 2005, 166: 511-20.
20. Wang, S., Zhan, M., Yin, J. et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006, 25: 3346-56.
21. Tran, N.L., McDonough, W.S., Donohue, P.J. et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003, 162: 1313-21.
22. Michaelson, J.S., Cho, S., Browning, B. et al. Tweak induces mammary epithelial branching morphogenesis. Oncogene 2005, 24: 2613-24.
23. Jakubowski, A., Ambrose, C., Parr, M. et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest 2005, 115: 2330-40.
24. Dempsey, P.W., Doyle, S.E., He, J.Q. and Cheng, G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003, 14: 193-209.
25. Han, S., Yoon, K., Lee, K. et al. TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors. Biochem Biophys Res Commun 2003, 305: 789-96.
26. Donohue, P.J., Richards, C.M., Brown, S.A. et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003, 23: 594-600.
27. Polek, T.C., Talpaz, M., Darnay, B.G. and Spivak-Kroizman, T. TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/ TweakR. Evidence for a second TWEAK receptor. J Biol Chem 2003, 278: 32317-23.
28. Xu, H., Okamoto, A., Ichikawa, J. et al. TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem Biophys Res Commun 2004, 318: 422-7.
29. Jin, L., Nakao, A., Nakayama, M. et al. Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J Invest Dermatol 2004, 122: 1175-9.
30. Kim, S.H., Kang, Y.J., Kim, W.J. et al. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004, 68: 396-9.
31. Campbell, S., Burkly, L.C., Gao, H.X. et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 2006, 176: 1889-98.
32. Dogra, C., Changotra, H., Mohan, S. and Kumar, A. Tumor necrosis factor-like weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD protein. J Biol Chem 2006, 281: 10327-36.
33. Polavarapu, R., Gongora, M.C., Winkles, J.A. and Yepes, M. Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor-kappaB pathway activation. J Neurosci 2005, 25: 10094-100.
34. Lynch, C.N., Wang, Y.C., Lund, J.K. et al. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999, 274: 8455-9.
35. Harada, N., Nakayama, M., Nakano, H. et al. Pro-inflammatory effect of TWEAK/ Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002, 299: 488-93.
36. Desplat-Jego, S., Varriale, S., Creidy, R. et al. TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol 2002, 133: 116-23.
37. Jakubowski, A., Browning, B., Lukashev, M. et al. Dual role for TWEAK in angiogenic regulation. J Cell Sci 2002, 115: 267-74.
38. Wilson, C.A. and Browning, J.L. Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis. Cell Death Differ 2002, 9: 1321-33.
39. Nakayama, M., Ishidoh, K., Kayagaki, N. et al. Multiple pathways of TWEAK-induced cell death. J Immunol 2002, 168: 734-43.
40. Nakayama, M., Ishidoh, K., Kojima, Y. et al. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 2003, 170: 341-8.
41. Perper, S.J., Browning, B., Burkly, L.C. et al. TWEAK is a novel arthritogenic mediator. J Immunol 2006, 177: 2610-20.
42. Saas, P., Boucraut, J., Walker, P.R. et al. TWEAK stimulation of astrocytes and the proinflammatory consequences. Glia 2000, 32: 102-7.
43. Chicheportiche, Y., Chicheportiche, R., Sizing, I. et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: Blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002, 4: 126-33.
44. Vince, J.E. and Silke, J. TWEAK shall inherit the earth. Cell Death Differ 2006, 13: 1842-4.
45. Carmeliet, P. Angiogenesis in health and disease. Nat Med 2003, 9: 653-60.
46. Ho, D.H., Vu, H., Brown, S.A.N. et al. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 2004, 64: 8968-72.
47. Nathan, C. Points of control in inflammation. Nature 2002, 420: 846-52.
48. Libby, P. Inflammation in atherosclerosis. Nature 2002, 420: 868-74.
49. Chicheportiche, Y., Fossati-Jimack, L., Moll, S., Ibnou-Zekri, N. and Izui, S. Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun 2000, 279: 162-5.
50. Zhang, X., Winkles, J.A., Gongora, M.C. et al. TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J Cereb Blood Flow Metab 2006, published online 12 July.
51. Splat-Jego, S., Creidy, R., Varriale, S. et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol 2005, 117: 15-23.
52. World Health Organization. World Health Report. Geneva 2003.
53. Lipton, P. Ischemic cell death in brain neurons. Physiol Rev 1999, 79: 1431-568.
54. Hawkins, B.T. and Davis, T.P. The bloodbrain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005, 57: 173-85.
55. Garcia, J.H., Lossinsky, A.S., Kauffman, F.C. and Conger, K.A. Neuronal ischemic injury: Light microscopy, ultrastructure and biochemistry. Acta Neuropathol (Berl) 1978, 43: 85-95.
56. Barnett, H.J., Taylor, D.W., Eliasziw, M. et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998, 339: 1415-25.
57. Munoz-Garcia, B., Martin-Ventura, J.L., Martinez, E. et al. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: Modulation by atorvastatin. Stroke 2006, 37: 2044-53.
58. Kurtzke, J.F. Clinical definition for multiple sclerosis treatment trials. Ann Neurol 1994, 36 Suppl: S73-9.
59. Hafler, D.A. Multiple sclerosis. J Clin Invest 2004, 113: 788-94.
60. Bernard, C.C., Johns, T.G., Slavin, A. et al. Myelin oligodendrocyte glycoprotein: A novel candidate autoantigen in multiple sclerosis. J Mol Med 1997, 75: 77-88.
61. Mueller, A.M., Pedre, X., Kleiter, I. et al. Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 159: 55-65.
62. Firestein, G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423: 356-61.
63. Bergers, G. and Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3: 401-10.
64. Tonini, T., Rossi, F. and Claudio, P.P. Molecular basis of angiogenesis and cancer. Oncogene 2003, 22: 6549-56.
65. Cao, Y. Antiangiogenic cancer therapy. Semin Cancer Biol 2004, 14: 139-45.